HDAC11 and cancer: Histone deacetylases, including sirtuin 6 (SIRT6) and histone deacetylase 11 (HDAC11), can promote glycolysis by suppressing the expression of intermediate signaling molecules, which in turn contributes to targeted therapy resistance in cancer cells [26, 194].